STOCK TITAN

Amneal (NYSE: AMRX) EVP awarded time- and performance-based RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Shah Nikita reported acquisition or exercise transactions in this Form 4 filing.

Amneal Pharmaceuticals Executive Vice President Nikita Shah received equity awards in the form of restricted stock units. She was granted 65,359 time-based restricted stock units and 65,359 performance-based restricted stock units, each representing a right to receive one share of Class A common stock.

The time-based units vest in four equal annual installments starting on March 2, 2027. The performance-based units are tied to average closing price targets over a three-year performance period, with potential payout from 0% to 200% of the target, and any earned units vesting on February 28, 2029.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shah Nikita

(Last) (First) (Middle)
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BLVD.

(Street)
BRIDGEWATER NJ 08807

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Vice President
3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 03/02/2026 A 65,359 (2) (2) Class A Common Stock 65,359 $0 65,359 D
Performance-Based Restricted Stock Units (3) 03/02/2026 A 65,359 (4) (4) Class A Common Stock 65,359 $0 65,359 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
2. The restricted stock units vest in four equal annual installments beginning on March 2, 2027.
3. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
4. Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.
Remarks:
/s/ Denis Butkovic, Attorney-in-Fact 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Amneal (AMRX) Executive Vice President Nikita Shah receive?

Nikita Shah received two equity awards: 65,359 restricted stock units and 65,359 performance-based restricted stock units. Each unit represents a contingent right to receive one share of Amneal’s Class A common stock, subject to vesting conditions over several years.

How do the time-based restricted stock units for Amneal (AMRX) EVP vest?

The time-based restricted stock units granted to Amneal Executive Vice President Nikita Shah vest in four equal annual installments. Vesting begins on March 2, 2027, and continues each year after that date, assuming the applicable service-based conditions are satisfied for each installment.

What determines vesting of the performance-based RSUs granted by Amneal (AMRX)?

The performance-based restricted stock units vest based on Amneal’s Class A common stock achieving specified average closing price targets over a three-year performance period. The number of shares earned may range from 0% to 200% of the target number specified in the award.

When do the performance-based RSUs for Amneal (AMRX) Executive Vice President vest if earned?

Any performance-based restricted stock units that are earned under the award vest in full on February 28, 2029. This date marks the last day of the three-year performance period used to measure the stock price targets governing the award’s payout.

How many shares can be issued under the performance-based RSU award at Amneal (AMRX)?

The award references 65,359 target performance-based restricted stock units. The number reported in the table represents the maximum shares issuable under the award, while the actual number earned can vary from 0% to 200% of the target based on performance.

What type of Form 4 activity occurred for Amneal (AMRX) Executive Vice President Nikita Shah?

The Form 4 reflects grant or award acquisitions of derivative securities, not open-market trades. It reports two acquisitions of restricted stock units and performance-based restricted stock units, each with 65,359 units, at a price of $0.0000 per unit as equity compensation.
Amneal Pharmaceuticals Inc

NASDAQ:AMRX

AMRX Rankings

AMRX Latest News

AMRX Latest SEC Filings

AMRX Stock Data

4.33B
155.86M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
Bridgewater